Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 Other Current Liabilities

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 (BLACR) currently reports a other current liabilities of $15M as of June 2026. That compares with $15M in the prior-year period — down 0.2% year over year. Use the charts on this page to explore Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's other current liabilities history and peer comparisons.

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's other current liabilities decreased from $15M to $15M — a 0.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 reported $15M in other current liabilities as of June 2026. That compares with $15M in the prior-year period — down 0.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $15M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028, and consider following BLACR for alerts when major investors trade the stock.